Compare BA & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BA | MRK |
|---|---|---|
| Founded | 1916 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 268.7B |
| IPO Year | 2005 | 1994 |
| Metric | BA | MRK |
|---|---|---|
| Price | $215.45 | $120.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 17 |
| Target Price | ★ $269.75 | $125.59 |
| AVG Volume (30 Days) | 6.8M | ★ 6.9M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | ★ 113.51 | 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,463,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $12.16 | $3.61 |
| Revenue Next Year | $14.78 | $5.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.50 | 1.31 |
| 52 Week Low | $176.77 | $76.66 |
| 52 Week High | $254.35 | $125.14 |
| Indicator | BA | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 60.69 |
| Support Level | $212.87 | $112.49 |
| Resistance Level | $228.02 | $124.09 |
| Average True Range (ATR) | 6.17 | 2.82 |
| MACD | -1.39 | 0.45 |
| Stochastic Oscillator | 19.41 | 83.03 |
Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).